Related Experiment Video

Updated: Oct 21, 2025

Isolation and Identification of Extravascular Immune Cells of the Heart
08:24

Isolation and Identification of Extravascular Immune Cells of the Heart

Published on: August 23, 2018

13.4K

Role of IL-37- and IL-37-Treated Dendritic Cells in Acute Coronary Syndrome

Ruirui Zhu1, Fangyuan Zhang2, Chengliang Pan1

  • 1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Oxidative Medicine and Cellular Longevity
|September 2, 2021
PubMed

Insights

Interleukin-37 (IL-37) shows promise for treating acute coronary syndrome (ACS). This protein reduces inflammation and may offer a new therapeutic strategy for this common heart condition.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Inflammation Research

Background:

  • Atherosclerosis, a chronic inflammatory disease, underlies acute coronary syndrome (ACS), a major cause of death and hospitalization.
  • Understanding ACS mechanisms and identifying novel therapeutic targets are critical.
  • Interleukin-37 (IL-37) is a natural inhibitor of innate and adaptive immunity, suppressing pro-inflammatory responses.

Purpose of the Study:

  • To investigate the role and therapeutic potential of Interleukin-37 (IL-37) in acute coronary syndrome (ACS).
  • To explore the immunomodulatory effects of IL-37 on dendritic cells (DCs) and their relevance to ACS.

Main Methods:

  • Analysis of IL-37 levels in patients with ACS.
  • Assessment of IL-37's effects on cardiac remodeling and ischemia/reperfusion injury in murine models.
  • Evaluation of IL-37's impact on dendritic cell (DC) function and cytokine secretion.

Main Results:

  • IL-37 levels were elevated and correlated with beneficial effects in patients with ACS.
  • IL-37 treatment alleviated cardiac remodeling and myocardial ischemia/reperfusion injury in preclinical models.
  • IL-37 induced tolerogenic properties in dendritic cells (DCs), characterized by increased immunosuppressive cytokine secretion.

Conclusions:

  • IL-37 exhibits a protective role in ACS and may serve as a novel therapeutic agent.
  • IL-37-modulated dendritic cells (tDCs) represent a potential cell-based therapy for ACS.
  • Further research is warranted to elucidate the precise mechanisms of IL-37 action in ACS.

More Related Videos

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.8K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
87
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
139
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
48
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
55